Dexcom beats second quarter estimates with 13% revenue growth and raises FY26 guidance.

DexCom reported second quarter 2026 revenue of $1.308 billion, up 13% year-over-year, and GAAP EPS of $0.64. The results prompted the company to raise its full-year 2026 guidance for both revenue and profitability margins.

Key Highlights

• Revenue grew 13% year-over-year to $1.308 billion, driven by 11% growth in the U.S. and 19% growth internationally.
• GAAP operating margin expanded significantly by 590 basis points to 24.3% compared to the second quarter of 2025.
• Dexcom raised its full-year 2026 revenue guidance to a range of $5.18 to $5.25 billion and increased its outlook for gross profit, operating, and adjusted EBITDA margins.